INRLF (Valneva SE) Valuation Rank


INRLF Valneva SE INRLF
60 GF Score
Price $2.62
GF Value $2.84
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Valneva SE Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Valneva SE Valuation Rank Related Terms

INRLF
60GF Score
Valneva SE INRLF
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Valneva SE (INRLF) Overvalued in 2026?

Based on GuruFocus' analysis, Valneva SE stock appears to be undervalued. The current stock price of $2.62 is trading 7.7% below its estimated GF Value™ of $2.84. GuruFocus considers Valneva SE to be Fairly Valued.

Key valuation signals for INRLF:

  • Valuation Rank:
  • GF Value™: $2.84 vs. price of $2.62 (7.7% below fair value)
  • GF Score™: 60/100 with 6 warning signs

No single metric tells the full story. See the INRLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Valneva SE Business Description

Address 12 ter Quai Perrache, Bureaux Convergence, Bat. A, Ilot Saint-Joseph, Lyon, FRA, 69002
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
60GF Score

Get the complete analysis for INRLF

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.62
Price
$2.84
GF Value